The webinar will feature presentations from Key Opinion Leaders (KOL’s) Amaal J. Starling, M.D. (Mayo Clinic College of Medicine and Science) and Stewart J. Tepper, M.D. (Geisel School of Medicine at Dartmouth University) who will discuss the current treatment landscape and unmet medical need in treating patients suffering from migraines.

Satsuma’s STS101, dihydroergotamine nasal powder, will be discussed as a novel investigational therapeutic product candidate for the acute treatment of migraine. John Kollins, Satsuma’s President & CEO, will provide a company update.

A live question and answer session will follow.